Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 study: long-term psychosocial consequences of childhood cancer

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 study: long-term psychosocial consequences of childhood cancer - SKION LATER Q2008-Psychosocial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47868

Enrollment

11800

Registered

2013-04-15

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kwaliteit van leven late effects of treatment for childhood cancer

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients who were treated for childhood cancer (before age 18) in one of the Pediatric Oncology Centers between 1960 and 2001 and who survived for at least 5 years after diagnosis will be included in the SKION LATER study. Participating centres are located in Amsterdam (VU University Medical Center (VUMC)), Groningen (Children's Cancer Center/ University Medical Center Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen (University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology (PMC)).

Exclusion criteria

Exclusion criteria: diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >17 years or diagnosis while residing in foreign country; no ability to read/write in Dutch

Design outcomes

Primary

Measure	Time frame
QoL(generic and survivor-specific), emotional functioning, anxiety, depression, PTSS, psychosocial predictors, namely: 1) Survivors = 18 jaar: - emotional functioning (GHQ-28) - generic QoL (TAAQOL) - health status (EQ-5d-Y) - developmental milestones (part of LVJV) - disease cognitions (ZCL) - self-esteem (Rosenberg Self-Esteem Scale) - impact van kanker (IOC-YA) - anxiety and depression (HADS) - PTSS (SRS-PTSS) 3) Siblings = 18jaar: - emotional functioning (GHQ-28) - generic QoL (TAAQOL) - health status (EQ-5d) - self-esteem (Rosenberg Self-Esteem Scale) - anxiety and depression (HADS) - PTSS (SRS-PTSS) 5) Parents: - emotional functioning (GHQ-28) - health status (EQ-5d) - PTSS (SRS-PTSS) - cognitions about the child's disease (ZCL) - parenting stress (NOSIK) - perceptions of child's disease (Child Vulnerability Scale) - executive functioning child	—

Measure

Time frame

QoL(generic and survivor-specific), emotional functioning, anxiety, depression, PTSS, psychosocial predictors, namely: 1) Survivors = 18 jaar: - emotional functioning (GHQ-28) - generic QoL (TAAQOL) - health status (EQ-5d-Y) - developmental milestones (part of LVJV) - disease cognitions (ZCL) - self-esteem (Rosenberg Self-Esteem Scale) - impact van kanker (IOC-YA) - anxiety and depression (HADS) - PTSS (SRS-PTSS) 3) Siblings = 18jaar: - emotional functioning (GHQ-28) - generic QoL (TAAQOL) - health status (EQ-5d) - self-esteem (Rosenberg Self-Esteem Scale) - anxiety and depression (HADS) - PTSS (SRS-PTSS) 5) Parents: - emotional functioning (GHQ-28) - health status (EQ-5d) - PTSS (SRS-PTSS) - cognitions about the child's disease (ZCL) - parenting stress (NOSIK) - perceptions of child's disease (Child Vulnerability Scale) - executive functioning child

—

Countries

Netherlands

Outcome results